7 news items
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
COYA
20 Jun 24
. No patient discontinued the study, and no deaths or other serious adverse events were reported.
Patients
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
COYA
11 Jun 24
, and no deaths or other serious adverse events were reported.
Patients' disease progression was measured
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
COYA
3 Jun 24
, and no deaths or other serious adverse events were reported.
Patients' disease progression
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease
COYA
22 May 24
on a conversation and respond to their environment. It is the sixth leading cause of death among all adults and the fifth leading cause for those aged 65 or older
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer's Drug Discovery Foundation (ADDF)
COYA
20 May 24
event was mild injection-site reactions. No patient discontinued the study, and no deaths or other serious adverse events were reported
jnq6v8bgftigpxe0bziuoqa6emsyb9bzk
COYA
26 Apr 24
to death and from diagnosis to death
Serum 4-HNE levels
wsp89rdcphwdxoyrle9mr
COYA
8 Apr 24
and survival of patients from ALS onset and diagnosis to death. During the Johnson Center Symposium, Dr. Appel will present data correlating 4-HNE
- Prev
- 1
- Next